ChoroPharma, LLC was founded in 2018 by Troy Chavis, a chemical engineer and molecular biologist, in Raleigh, North Carolina. The company focuses on developing and manufacturing complex, first-to-market generic pharmaceuticals, with a particular emphasis on ophthalmic drug products. ​

​

In its early years, ChoroPharma established a formulation development laboratory in Research Triangle Park, North Carolina. This facility enables the company to conduct comprehensive drug development studies for complex ophthalmic products, including formulation optimization and stability assessments. By the end of its first year, ChoroPharma completed development reports for four products, adhering to Quality by Design (QbD) principles. ​

​

​

ChoroPharma's business model encompasses product development, analytical testing, contract manufacturing, and licensing. The company values partnerships and collaborations as integral to building a sustainable business with long-term growth potential. ​

​

By focusing on the development of high-quality generic ophthalmic medications, ChoroPharma aims to address the significant demand and supply shortages in the billion-dollar ophthalmic market, positioning itself as an influential niche company in this sector. ​